

Insys Therapeutics
1333 South Spectrum Blvd., Suite 100
Chandler, AZ 85286

Office of the Governor
1205 Pendleton Street
Columbia SC 29201

December 19th, 2014

Dear Hal Peters,

I would like to take this opportunity to introduce you to Insys Therapeutics (ticker symbol on Nasdaq: INSY), a US based specialty pharmaceutical company that is committed to cannabinoid clinical research. In our cannabinoid platform, we are currently marketing and developing products with Tetrahydrocannabinol (THC), which is an active ingredient of marijuana. We are also developing pharmaceutical products using cannabidiol (CBD), a non-psychoactive component originating from the marijuana plant for epilepsy and other conditions.

Notably, our THC and CBD are synthetically produced (non-plant based) and are of pharmaceutical grade purity but are chemically identical to plant-derived CBD. Please see our attached press release where we discuss working with NIDA (National Institute on Drug Abuse) to carry out this analysis that determined our synthetically produced CBD is chemically identical to plant-derived CBD. .

We anticipate that our CBD medication will be available for epilepsy clinical trials by the first quarter of 2015 and we would very much like to work with you to provide these options to patients in your state. Please reach out to our VP Corporate Development, Vikram Malhotra, email: vmalhotra@insysrx.com; P: (480) 500-3164, to coordinate the logistics for a phone call or in-person meeting to discuss how we can mutually work together and help patients who may need CBD.



Best regards,
Michael L. Babich
President and CEO
Insys Therapeutics



For Immediate Release

Parallel Comparison Analyses Confirm that Insys Therapeutics' Synthetic CBD is Identical in Chemical Structure to Plant-Derived CBD

PHOENIX, AZ – December 3, 2014 – Independent comparison analyses have found that cannabidiol (CBD) synthetically produced by Insys Therapeutics, Inc. (Nasdaq: INSY) is chemically identical to plant-derived CBD. Analyses were conducted independently by Insys and the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

The two separately-conducted analyses ascertained that Insys' synthetically produced CBD:

- Has identical identity and chemical structure to plant-derived CBD;
- Has identical stereochemistry to plant-derived CBD; both demonstrated the same (-) CBD enantiomer with no (+) enantiomer present, which was confirmed by Chiral Assay;
- Is more pure, with a 2% higher CBD Assay value than plant-derived CBD;
- Insys CBD total HPLC purity 99.9% vs. plant-derived CBD at 98.7%; and,
- Meets all ICH impurity guidelines, with no impurities greater than 0.10%, vs. plant-derived CBD which contained multiple impurities above ICH guidelines.

“The results of NIDA’s analyses confirm those conducted in our laboratories, demonstrating that our CBD is identical in chemical structure to plant-derived CBD as determined by multiple methods,” said Michael L. Babich, President and Chief Executive Officer of Insys. “We believe our product’s purity levels will provide consistent material for our clinical programs, including our program to evaluate CBD in pediatric patients suffering from Dravet Syndrome and Lennox-Gastaut Syndrome. We plan to dose our first human subjects in the first quarter of 2015 in a Phase I setting.”

For these independent comparison analyses, both organizations utilized NIDA-supplied natural, plant-derived CBD and synthetically produced CBD supplied by Insys. Insys' synthetic, pharmaceutical CBD is manufactured under cGMP conditions at its FDA-inspected and Drug Enforcement Administration (DEA)-approved facility in Round Rock, Texas, and therefore Insys manufactured CBD has greater batch-to-batch consistency and uniformity. Insys believes that it is the only U.S.-based company with the capacity to produce pharmaceutical cannabinoids in scalable quantities.

NIDA, a component of the National Institutes of Health, U.S. Department of Health and Human Services, supports most of the world's research on the health aspects of drug abuse and addiction. Insys has been approved as a qualified supplier of CBD to NIDA, and NIDA will refer CBD requests (from state agencies, research projects, clinical trials, etc.) directly to Insys.

About Insys Therapeutics, Inc.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, Subsys[®], which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules. Our lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of Dronabinol. Insys is also developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.

Subsys[®] is a registered trademark of Insys Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding Insys' pharmaceutical CBD development program, including timing of the planned clinical trial of a product related to CBD for Dravet Syndrome and Lennox-Gastaut Syndrome, the ability of Insys to provide adequate quantities of CBD sufficient to pursue its CBD development program, and Insys' capability to provide uninterrupted, domestic supply of CBD. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. For a description of these risks facing the company, please see the risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2013 and any subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.

Contact:

For Insys Therapeutics

Lisa M. Wilson

President

In-Site Communications, Inc.

T: 212-452-2793

E: lwilson@insitecony.com

Use of this system constitutes your agreement to the service conditions in the current FedEx Service Guide, available on fedex.com. FedEx will not be responsible for any claim in excess of \$100 per package, whether the result of loss, damage, delay, non-delivery, misdelivery, or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim. Limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic value of the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental, consequential, or special is limited to the greater of \$100 or the authorized declared value. Recovery cannot exceed actual documented loss. Maximum for items of extraordinary value is \$1,000, e.g. jewelry, precious metals, negotiable instruments and other items listed in our Service Guide. Written claims must be filed within strict time limits, see current FedEx Service Guide.

RECEIVED

DEC 29 2014

referred to Hal

Answered _____

After printing this label:
CONSIGNEE COPY - PLEASE PLACE IN FRONT OF POUCH
1. Fold the printed page along the horizontal line.
2. Place label in shipping pouch and affix it to your shipment.

From: (602) 910-2617
INSYS THERAPEUTICS
INSYS THERAPEUTICS
1333 S. SPECTRUM BLVD
#100
CHANDLER, AZ 85286

Origin ID: CHDA



J141214073003uv

Ship Date: 19DEC14
ActWgt: 1.0 LB MAN
CAD: 0435278/CAFE2806

Delivery Address Bar Code



SHIP TO:
HAL PETERS
OFFICE OF THE GOVERNOR
1205 PENDLETON STREET

COLUMBIA, SC 29201


BILL SENDER

Ref #
Invoice #
PO #
Dept #

TUE - 23 DEC AA
**** 2DAY ****


TRK# 6273 4721 7776

0201



SH USCA

29201
SC-US
CAE



52102J0756F03